BioProspect Limited is an Australian company engaged in developing and commercialising natural products and technology in the human health and personal care, animal health and nutrition and agricultural sectors.

ASX/Media Announcements

February 2012

Frontier drill rig Nassiping -2 (SC52) spuds

Update Frontier drill rig Nassiping -2 (SC52)

Market Update

Review of Corporate Governance Procedures

January 2012

Appendix 4C 31 December 2011

Response to Otto Energy comments

AGRIPRO development update

Frontier Gasfields update on Philippines drilling prospects

December 2011

Change of Director's Interest Notice

November 2011

Results of AGM

October 2011

Appendix 4C Sept qtr 2011

Notice of AGM and Proxy Form

Annual Report to Shareholders

Update Frontier's Philippines SC52 gas exxploration

Change of Registered Office

GI-GUARD Oral Paste in horses update

September 2011

Final Statutory accounts

Appendix 3B

Sept issue of Bionews

Final director's interest notice

Initial Director's interest notice

Appointment of Director

Resignation of Director

August 2011

Preliminary final report

Convertible Note Issue

Appendix 3B

Increase in shareholding in Frontier Gasfields

Final Director's Interest Notice

July 2011

Appendix 4C June qtr

3D Seismic survey completed on Frontier's SC6 project

Appendix 3B

Frontier's Philippines SC52 gas exploration advance

Appendix 3B

Middle East agreements for AGRIPRO and GI-Guard

Resignation of Director

Frontier investment finalised

Appendix 3Y MQ

Appendix 3Y CP

Appendix 3Y AL

Appendix 3Y JK

Appendix 3B

Appendix 3B

Results of Extraordinary General Meeting

June 2011

Re Gen Wellness Products newsletter

Notice of extraordinary general meeting 8 July

May 2011

Frontier Gasfields extension of exclusivity period

April 2011

Completion of due diligence Frontier Gasfields

March issue of Bionews

March 2011

Update on Frontier Gasfields due diligence 31 March

Update on Frontier Gasfields due diligence 10 March

Response to ASX on BPO announcement 3 March

New investment into gas assets

February 2011

Appendix 4D and half year accounts

Appendix 3X J Khouri

GI-GUARD Oral Paste Development update

Appointment of Director

Placement and Appendix 3B

Distribution agreement for REGEN products

January 2011

Appendix 4C 31 December 2010

Appendix 3B

December 2010

REGEN business update

Securities Trading Policy

GI-GUARD Oral Paste -APVMA update

Top 20 holders Options  (BPOO)

Change of Director's Interest Notice App 3Y

Appendix 3B Request for quotation of Options

Appendix 3B Final Rights Issue

Change of Director's Interest Notice

Rights issue take up

November 2010

AGM Results

AGM presentation

Response to Solagran's AGM presentation

Prospectus dispatched to shareholders Nov 10

Supplementary Prospectus 1 Nov

October 2010

Appendix 4C 30 September 2010

Update on legal dispute with Solagran Limited

Notice of Annual General meeting & Proxy Form

Annual Report 2010

Prospectus clarification

Letter to shareholders & optionholders for Rights Issue

Rights Issue Prospectus

Announcement of Rights Issue & Appendix 3B

Termilone Project Update

Share Placement, App 3B and Rights Issue

October issue of Bionews

September 2010

Final Accounts for year ended 30 June 2010

Update on federal court hearing with Solagran

Appendix 3Y Change of Director's Interest Notice

Supply of CGNC secured

Resignation of Director

Update on dispute with Solagran Limited

Update on dispute with Solagran Limited

August 2010

Preliminary Final Report and Appendix 4E

Update on dispute with Solagran Limited

Dispute with Solagran Limited

July 2010

Appendix 4C 30 June 2010

Dispute with Solagran Limited

Development Agreement with Solagran Limited

June 2010

Termilone trials update

Development Agreement with Solagran Limited

Resignation of Director and Appendix 3Z

Appendix 3Y Change of Director's interest notice

2010 SPP results and Appendix 3B

GI-GUARD horse treatment submitted for regulatory approval

Results of General Meeting

General meeting presentation

May 2010

Agripro natural animal health products update

Update on Re Gen Wellness Products

Share Purchase Plan extension to 11 June

Termilone commercialisation update

Share Purchase Plan Issue Price and Terms

Share Purchase Plan clarification

April 2010
Share Placement & Appendix 3B

Notice of General Meeting

Share Purchase Plan announcement

Appendix 4C 31 March 2010

Termilone CSIRO trial results

March 2010
Bionews March 2010 issue

Expiry of Listed Options

Successful horse safety studies

Appendix 3B

February 2010
Half year reports and accounts

BioProspect and Solagran  agree to commercialise

APVMA approval for Termilone

January 2010
Appendix 4C 31 Dec 2009

Capital placement and Appendix 3B

Qcide Intellectual Property agreement

December 2009
Ensystex market development agreement
November 2009
Appointment of COO

AGM Results of meeting

AGM presentation slides

Appointment of Managing Director

October 2009
Appendix 4C 30 Sept 09

Appendix 3Y Change of Director's interests

Notice of AGM and Proxy Form

Annual Report to Shareholders

October issue of Bionews

September 2009
Appendix 3X

Audited accounts y/e 30 June 2009

Board Appointment

Appendix 3X

Appendix 3B

August 2009
Board Appointment

Appendix 4E & preliminary results y/e June 2009

BioProspect concludes Re-Gen acquisition

July 2009
Appendix 4c 30 June 2009

Agreement to acquire Re-Gen Wellness Products

Major safety study on horses with Bioeffective A

Termilone registration update with APVMA

May 2009
HOA to purchase Re-Gen Wellness Products
April 2009
Appendix 4C 31 March 2009

Response to ASX query

Final Director's Notice Appendix 3Z

Mr Peter Stedwell

March 2009
March issue of Bionews
February 2009
Appendix 4D & Half-year accounts
January 2009
Appendix 4C 31 Dec 2008
Ensystex evaluation agreement
November 2008
Final director's interest notice S Morrow
Final director's interest notice P Landau
AGM results
AGM CEO's presentation
Director Resignations
Termilone reg'n lodged with APVMA
October 2008
Appendix 4C 30 Sept 08
Chairman's letter and Notice of AGM
2008 AAnnual Report
Update on Sect 249D Notice of requisition for GM
Australian patent granted for Termilone
Section 249D Notice of requisition for GM
September 2008
Appointment of CEO
Final Director's Interest Notice
Board changes
Section 249D notice withdrawn
August 2008
Appendix 4E and preliminary final report
Completion of sale of ANZ securities
Poultry trial results-Bioeffectives
EGUS trial results -Bioeffectives
Inhalation toxicity results Termilone
Section 249D notice of requisition for GM
July 2008
Appendix 4C 30 June 2008
June 2008
Resignation of Managing Director 25 June
Qcide licence agreement-Bio-Gene  24 June
Termilone video script by MD 6 June
May 2008
Termilone 28 day dermal toxicity results 1 May
April 2008
Takeovers Panel decision 28 April
Appendix 4C 31 March
Bioeffectives screening trial Dubai 24 April
TERMILONE bioassay result 8 April
ANZ substantial holder notice 7 April
Takeovers Panel response4 April
Takeovers Application 3 April
ASX response 3 April
March 2008
Change of Director interests WD
Change of Director interests PL
February 2008
Appendix 3B 28 Feb
Half year accounts and App 4D
January 2008
Appendix 4C 31 December 2007
Change of Director interests MQ
Change of Director interests SM
Change of Director interests PL
December 2007
Interview with MD by Investor TV
Appendix 3B 7 Dec
Termilone Toxicity Results
November 2007
Appendix 3B 15 Nov
BioProspect Change of Share Registrars
BioProspect AGM commentary for shareholders
BioProspect AGM Presentation 5th Nov
AGM results 5 Nov
Appendix 3B 1 Nov
October 2007
Appendix 4C 30 Sept
Change of address 11 Oct
Letter to shareholders 5 Oct
AGM Notice of Meeting and Proxy Form 5 Oct
2007 Annual Report
August 2007
Appendix 4E & Preliminary annual report
Solagran Licence Agreement signed
Solagran Licence Agreement signed-media release
July 2007
Appendix 4C 30 June 2007
Top 20 option holders and Appendix 3B
Completion of underwriting and Appendix 3B
Change of Director's Interest Notice 16 July
June 2007
Option Underwriting Agreement 18 June
Initial Director's Interest Notice 18 June
Chairman Appointment 18 June
General Meeting Results 8 June
May 2007
Initial Director's Interest Notice 31 May
Final Director's Interest Notice 31 May
Board Changes 31 May
Options Expiry Notice 29 May
Solagran due diligence complete 29 May
Notice of meeting 8 June
April 2007
Appendix 4C March qtr
Initial Director's Interest Notice
Final Director's Interest Notice
Heads of Agreement with Solagran Limited
February 2007
Toxicity test results-Termilone
Appendix 4D and half-year accounts
Completion of placement
Appendix 3B
Capital Raising
January 2007
31 Dec 2006 quarterly report and Appendix 4C
Response to ASX Price Query
November 2006
AGM Poll Results 29 November
AGM General Manager's presentation
ENSIS/CSIRO Agreement
Response to ASX Price Query
October 2006
Appendix 4C 30 September
Field trial update
September 2006
Notice of Annual General Meeting
Appendix 4E & Annual Report 30 June 2006
July 2006
Appendix 4C 30 June 2006
May 2006
Appendix 4C 31 March 2006
April 2006
Executive Appointment
March 2006
ASX Price Query
Appendix 4D Half Yearly Report and Accounts 31 December 2005
February 2006
AP778 Field trial update
January 2006
Quarterly Report 31 December 2005 and Appendix 4C
Expiry of 25 January 2006 Options
Despatch of Prospectus